Você procurou por: bloodstream infection (Grego - Inglês)

at risk of infection
patients deemed at risk of infection

treatment of adenovirus infection in immunocompromised patients
treatment of adenovirus infection in

treatment of diarrhoea associated with intestinal microsporidial infection
treatment of diarrhoea associated with intestinal

mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of escherichia coli.
mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of escherichia coli.

active immunisation against hepatitis b virus infection caused by all known subtypes in children and adolescents
caused by all known subtypes in

single- dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:
single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:

he determined that inhaling pressurized air caused the nitrogen to dissolve into the bloodstream; rapid depressurization would then release the nitrogen into its natural gaseous state, forming bubbles that could block the blood circulation and potentially cause paralysis or death.
he determined that inhaling pressurized air caused the nitrogen to dissolve into the bloodstream; rapid depressurization would then release the nitrogen into its natural gaseous state, forming bubbles that could block the blood circulation and potentially cause paralysis or death.

Τίτλος εγγράφου points to consider on the clinical development of fibrinolytic medicinal products in the treatment of patients with st segment elevation acute myocardial infarction (stemi) note for guidance on the clinical development of medicinal products for the treatment of hiv infection.
note for guidance on clinical investigation of medical products in the treatment of generalised anxiety disorder

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti-d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)